Dactolisib not checked
Restorbio Inc. · RTB101 · BEZ235
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
- How it’s given
- “Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks”In the company’s words, NCT04584710 on ClinicalTrials.gov
- Tested for
- Covid19
- Main trialPhase 2
- “The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.”In the company’s words, NCT04584710 on ClinicalTrials.gov
- Other names
- RTB101 · BEZ235
Other drugs for Covid19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Feb 2021 | A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults | |
| Phase 3Completed | 2 Dec 2019 | A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly | |
| Phase 2Terminated | 27 Dec 2020 | Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026